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Background. Hedgehog (Hh) signaling is essential for osteoblast diﬀerentiation of mesenchymal progenitors during endochondral
bone formation. However, the critical role of Hh signaling during adult bone remodeling remains to be elucidated. Methods. A
Smoothened (SMO) antagonist/Hedgehog inhibitor, BMS-833923, identiﬁed during a functional screening of a stem cell
signaling small molecule library, was investigated for its eﬀects on the osteoblast diﬀerentiation of human skeletal
(mesenchymal) stem cells (hMSC). Alkaline phosphatase (ALP) activity and Alizarin red staining were employed as markers for
osteoblast diﬀerentiation and in vitro mineralization capacity, respectively. Global gene expression proﬁling was performed
using the Agilent® microarray platform. Eﬀects on in vivo ectopic bone formation were assessed by implanting hMSC mixed
with hydroxyapatite-tricalcium phosphate granules subcutaneously in 8-week-old female nude mice, and the amount of bone
formed was assessed using quantitative histology. Results. BMS-833923, a SMO antagonist/Hedgehog inhibitor, exhibited
signiﬁcant inhibitory eﬀects on osteoblast diﬀerentiation of hMSCs reﬂected by decreased ALP activity, in vitro mineralization,
and downregulation of osteoblast-related gene expression. Similarly, we observed decreased in vivo ectopic bone formation.
Global gene expression proﬁling of BMS-833923-treated compared to vehicle-treated control cells, identiﬁed 348 upregulated
and 540 downregulated genes with signiﬁcant eﬀects on multiple signaling pathways, including GPCR, endochondral
ossiﬁcation, RANK-RANKL, insulin, TNF alpha, IL6, and inﬂammatory response. Further bioinformatic analysis employing
Ingenuity Pathway Analysis revealed signiﬁcant enrichment in BMS-833923-treated cells for a number of functional categories
and networks involved in connective and skeletal tissue development and disorders, e.g., NFκB and STAT signaling.
Conclusions. We identiﬁed SMO/Hedgehog antagonist (BMS-833923) as a powerful inhibitor of osteoblastic diﬀerentiation of
hMSC that may be useful as a therapeutic option for treating conditions associated with high heterotopic bone formation and
mineralization.
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1. Introduction
The Hedgehog (Hh) signaling pathway plays many
important roles during development and postnatal tissue
homeostasis including bone formation [1]. In mammals,
the hedgehog family is composed of three protein members:
Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), and Desert
Hedgehog (Dhh) [2, 3]. The negative and positive cellular
regulation of Hh is controlled by two transmembrane pro-
teins, Patched (Ptc), a negative regulator of Hh signaling,
and Smoothened (Smo), a GPCR-like 7-transmembrane
receptor that stimulates downstream signaling in response
to Hh [3, 4]. Thus, an inhibition of Hh signaling conse-
quently inhibits SMO activity [3].
Human skeletal (mesenchymal) stem cells (hMSC) are
multipotent stem cells found in the bone marrow and can
give rise to various mesoderm cell types including bone-
forming osteoblasts [5]. The osteoblastic diﬀerentiation of
hMSCs is controlled by multiple signaling pathways [6]
including Hh signaling [1], TGFβ [7], bone morphogenetic
proteins [8], and Wnt/β-catenin [9]. The Hh protein
enhances the diﬀerentiation of hMSCs into osteoblastic line-
age and increases the expression of ALP and in vitro forma-
tion of the mineralized matrix which are markers of mature
osteoblast functions [10]. Moreover, a disruption of the Hh
pathway has been associated with a number of developmen-
tal bone diseases [1].
Small molecule inhibitors are currently used as valuable
tools to decipher the molecular mechanisms regulating stem
cell diﬀerentiation, and they have potential therapeutic use
[11, 12]. Speciﬁcally, the small molecule agonist or antagonist
regulators of the Hh pathway, could potentially be used to
treat bone diseases. Here, we identiﬁed a small molecule
BMS-833923, an inhibitor of SMO and the Hh pathway,
through a small molecule library screen [11] and character-
ized its functions in vitro and in vivo on hMSC diﬀerentia-
tion to bone-forming osteoblastic cells.
2. Materials and Methods
2.1. Cell Culture. A hMSC-TERT cell line was used in this
study as a model for hMSCs [13, 14]. hMSC-TERT expresses
all features of primary hMSCs including multipotency and
molecular signature [13, 14]. The cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM), a basal
medium supplemented with 4mM L-glutamine, 4,500mg/l
D-glucose, and 110mg/l 10% sodium pyruvate, in addition
to 10% fetal bovine serum (FBS), 1% penicillin-streptomycin,
and 1% nonessential amino acids. All reagents were pur-
chased fromThermo Fisher Scientiﬁc Life Sciences,Waltham,
MA (http://www.thermoﬁsher.com). Cells were incubated in
5% CO2 incubators at 37
°C and 95% humidity.
2.2. Osteoblast Diﬀerentiation. The cells were maintained
until 80%–90% conﬂuency was achieved; then, the
medium was replaced with osteoblast induction medium
(DMEM containing 10% FBS, 1% penicillin-streptomycin,
50mg/mL L-ascorbic acid (Wako Chemicals GmbH,
Neuss, Germany,http://www.wako-chemicals. de/), 10mM
b-glycerophosphate (Sigma-Aldrich), 10 nM calcitriol
(1a,25-dihydroxyvitamin D3, Sigma-Aldrich), and 10nM
dexamethasone (Sigma-Aldrich). The stem cell signaling
small molecule inhibitor library and BMS-833923 were
obtained from Selleckchem Inc. (Houston, TX, http://www
.selleckchem.com). Each small molecule inhibitor was added
at 3μM concentration to the osteoblast induction medium,
and cells were exposed to the inhibitor throughout the diﬀer-
entiation period. Control cells were treated with osteoblast
induction medium containing dimethyl sulfoxide (DMSO)
as vehicle.
2.3. Cell Viability Assay. Cell viability assay was performed
using an alamarBlue assay according to the manufacturer’s
recommendations (Thermo Fisher Scientiﬁc). Cells were cul-
tured in 96-well plates in 300μL of the medium. On day 10,
30μL/well of alamarBlue substrate was added (10%) and
plates were incubated for 1 hr in the dark at 37°C. Readings
were obtained using the BioTek Synergy 2 Microplate Reader
(BioTek Instruments Inc., Winooski, VT, US) at ﬂuorescent
mode (ex: 530 nm/em: 590nm).
2.4. Quantiﬁcation of Alkaline Phosphatase Activity. Alkaline
phosphatase (ALP) activity quantiﬁcation was assessed using
the BioVision ALP Activity Colorimetric Assay Kit (BioVi-
sion, Inc., Milpitas, CA, http://http://www.biovision.com/)
with some modiﬁcations. The cells were cultured in 96-well
plates. At day 10 of osteoblast diﬀerentiation, cells were
rinsed once with PBS and ﬁxed using 3.7% formaldehyde in
90% ethanol for 30 seconds at room temperature. The ﬁxa-
tive was removed and 50μL/well of p-nitrophenyl phosphate
solution was added and incubated for 30–60minutes. Optical
densities were then measured at 405nm using a Spectra-
Max/M5 ﬂuorescence spectrophotometer plate reader, and
ALP enzymatic activity was then normalized to cell number.
2.5. Alkaline Phosphatase Staining. Cells were cultured in a
6-well plate in osteoblast diﬀerentiation medium. On day 10,
the cells were washed in PBS and ﬁxed in 10mM acetone/-
citrate buﬀer at pH4.2 for 5min at room temperature. Theﬁx-
ative was removed and Naphthol/Fast Red stain (0.2mg/mL
Naphthol AS-TR phosphate substrate (Sigma-Aldrich);
0.417mg/mL of Fast Red (Sigma-Aldrich)) was added for
1 hr at room temperature. Then, cells were washed with water
3 times and images were taken under the microscope.
2.6. Alizarin Red S Staining for Mineralized Matrix
Formation. On day 21 of osteoblast diﬀerentiation, cells were
washed twice with PBS and ﬁxed with 4% paraformaldehyde
for 10min at room temperature. The ﬁxative was rinsed, and
the cells were then washed 3 times with distilled water and
stained with the 2% Alizarin Red S Staining Kit (ScienCell
Research Laboratories, Cat. No. 0223) for 10–20min at room
temperature. Later, the cells were washed with water and
images were taken under the microscope.
2.7. RNA Extraction and cDNA Synthesis. Total RNA was
extracted from cell pellets on day 10 of osteoblast diﬀeren-
tiation using the Total RNA Puriﬁcation Kit (Norgen Bio-
tek Corp., Thorold, ON, Canada, https://norgenbiotek
.com/) according to the manufacturer’s instructions. The
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concentrations of total RNA extracted were then measured
using NanoDrop 2000 (Thermo Fisher Scientiﬁc Life Sci-
ences). cDNAwas synthesized with 500 ng of total RNA using
the High-Capacity cDNA Transcription Kit (Thermo Fisher
Scientiﬁc Life Sciences) according to the manufacturer’s
instructions.
2.8. Quantitative Real Time-Polymerase Chain Reaction.
Quantitative Real Time-Polymerase Chain Reaction
(RT-PCR) was performed with fast SYBR Green using the
Applied Biosystems ViiA™ 7 Real-Time PCR System
(Thermo Fisher Scientiﬁc Life Sciences). Primers used in this
study are listed in Table 1. Relative expression was calculated
using the 2ΔCT value method, and analysis was made as
previously described [15].
2.9. Gene Expression Proﬁling by Microarray. One hundred
ﬁfty nanograms of total RNA from day 10 of osteoblast dif-
ferentiation was labeled using a low-input Quick Amp Label-
ing Kit (Agilent Technologies, Santa Clara, CA, http://www
.agilent.com) and hybridized to the Agilent Human
SurePrint G3 Human GE 8 × 60 k microarray chip. All
microarray experiments were performed at the Microarray
Core Facility (Stem Cell Unit, Department of Anatomy, King
Saud University College of Medicine, Riyadh, Saudi Arabia).
Data were normalized and analyzed using GeneSpring 13.0
software (Agilent Technologies). Pathway analyses were com-
pleted using GeneSpring 13.0 as described previously [16].
Twofold cutoﬀ and PðcorrÞ < 0:05 (Benjamini-Hochberg
multiple testing corrected) were set to deﬁne signiﬁcantly
changed transcripts. Pathway and functional annotation anal-
yses were conducted using the Ingenuity Pathway Analysis
(Ingenuity Systems, http://www.ingenuity.com/) [17, 18].
Downregulated genes ≤ 2 FC (fold change) and corrected
P value < 0.05 were chosen for analysis. Enriched network
categories were algorithmically generated based on their con-
nectivity and ranked according to Z score.
2.10. In Vivo Ectopic Bone Formation Assay. Ethical approval
for all animal experiments was obtained from the Animal
Care Committee of King Saud University. In vivo experi-
ments were performed as previously described [19]. In brief,
cells were trypsinized to a single-cell suspension and resus-
pended in culture medium with/without the small molecule
inhibitor, BMS-833923. Around 5 × 105 cells were seeded
onto 40mg Triosite hydroxyapatite-tricalcium phosphate
granules per implant (HA/TCP, Biomatlante/Zimmer,
Albertslund, Denmark) with 0.5 to 1mm granules, and kept
overnight at 37°C and 5% CO2. HA/TCP granules in combi-
nation with cells were then implanted subcutaneously (four
implants per cell line) in the dorsolateral area of immune-
compromised nude mice for 8 weeks. The implants were
recovered, ﬁxed in formalin, decalciﬁed using formic acid
solution (0.4M formic acid and 0.5M sodium formate) for
three days, embedded, and sectioned at 4μm. Staining was
performed with hematoxylin and eosin or Sirius Red to iden-
tify areas of formed bone.
2.11. Quantiﬁcation of Ectopic Bone Formation. Slides were
digitized using a high-resolution whole-slide digital Scan-
Scope scanner (Aperio Technologies, Inc.). The digital
images from hematoxylin and eosin-stained slides were
viewed and quantiﬁed using the tools of ImageJ software.
The whole implant was contoured to acquire the total
implant area in pixels (TA). All areas of bone are selected
to obtain total bone area in pixels (BA). The BA/TA ratio
was calculated and reported as percentage (n = 3 sections
per implant and 4 implants/condition). The digital images
Table 1: List of SYBR Green primers used in current study.
Gene name Forward primer Reverse primer
ACTB 5′AGCCATGTACGTTGCTA3′ 5′AGTCCGCCTAGAAGCA3′
ALPL 5′GGAACTCCTGACCCTTGACC3′ 5′TCCTGTTCAGCTCGTACTGC3′
COL1A1 5′GAGTGCTGTCCCGTCTGC3′ 5′TTTCTTGGTCGGTGGGTG3′
ON 5′GAGGAAACCGAAGAGGAGG3′ 5′GGGGTGTTGTTCTCATCCAG3′
LIF 5′GCCACCCATGTCACAACAAC3′ 5′CCCCCTGGGCTGTGTAATAG3′
CXCL1 5′CCAGCTCTTCCGCTCCTC3′ 5′CACGGACGCTCCTGCTG3′
CXCL2 5′GGGGTTCGCCGTTCTCGGA3′ 5′TGCGAGGAGGAGAGCTGGCAA3′
CXCL3 5′CGCCCAAACCGAAGTCATAGCCA3′ 5′TGGTAAGGGCAGGGACCACCC3′
IL6 5′CGAGCCCACCGGGAACGAAA3′ 5′GGACCGAAGGCGTTGTGGAG3′
PLAU 5′ACTCCAAAGGCAGCAATGAAC3′ 5′GTGCTGCCCTCCGAATTTCT3′
TNF 5′ACTTTGGAGTGATCGGCC3′ 5′GCTTGAGGGTTTGCTACAAC3′
CCL20 5′CGAATCAGAAGCAGCAAGCAA3′ 5′TTGCGCACACAGACAACTTT3′
VCAM 5′TGTTTGCAGCTTCTCAAGCTTTT3′ 5′GATGTGGTCCCCTCATTCGT3′
GLI1 5′CTGGATCGGATAGGTGGTCT3′ 5′CAGAGGTTGGGAGGTAAGGA3′
PTCH1 5′TGACCTAGTCAGGCTGGAAG3′ 5′GAAGGAGATTATCCCCCTGA3′
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from Sirius red-stained slides were viewed and analyzed
using Aperio’s viewing and image analysis tools. In each
slide, ﬁve rectangular ﬁelds with a ﬁxed area of 1.18mm2
(total analysis area) were randomly selected. A color deconvo-
lution algorithm (Aperio Technologies, Inc.) was employed to
measure areas of the red color of stained collagen (positive
staining of Sirius red), and its percentage relative to the total
area was calculated (n = 4 implants per treatment).
2.12. Statistical Analysis. Statistical analysis and graphing
were assessed using Microsoft Excel 2010 and GraphPad
Prism 6 Software (GraphPad Software, San Diego, CA,
U.S.A.), respectively. Results were presented as mean ± SEM
from at least two independent experiments. An unpaired,
two-tailed Student’s t-test was used to calculate statistical sig-
niﬁcance, and P values < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. BMS-833923 Inhibited Osteoblast Diﬀerentiation of
hMSCs. BMS-833923 was initially identiﬁed as a potent
inhibitor (at 3μM) of hMSC osteoblastic diﬀerentiation
based on a functional small molecule library screen [11].
hMSCs exposed to BMS-833923 (3μM) exhibited a signiﬁ-
cant decrease in ALP cytochemical staining and ALP activity
compared to DMSO-vehicle control cells (Figures 1(a)–1(b))
but did not exert signiﬁcant eﬀects on hMSC cell viability
(Figure 1(c)). Also, hMSCs exposed to BMS-833923 exhib-
ited a signiﬁcant reduction in mineralized matrix formation
as stained with Alizarin red, compared to vehicle-treated
controls (Figure 2(a)) which was associated with a signiﬁcant
reduction in the expression of a number of osteoblast gene
markers: ALP, COL1A1, and ON (Figure 2(b)). To conﬁrm
that BMS-833923 is indeed targeting the hedgehog signaling
pathway, hMSCs were treated with BMS-833923 at the same
concentration (3μM), and 48 hrs later, the expression of GLI
Family Zinc Finger 1 (GLI1) and Patched 1 (PTCH1), down-
stream readouts of the hedgehog signaling pathway, was
assessed using qRT-PCR. Data presented in Figure 2(c) dem-
onstrated signiﬁcant inhibition of the hedgehog signaling
pathway by BMS-833923. These data demonstrate that
BMS-833923 exerts inhibitory eﬀects on osteoblast diﬀerenti-
ation and mature osteoblastic cell functions, through the
inhibition of the hedgehog signaling pathway.
3.2. Global Gene Expression Identiﬁed Multiple Altered
Signaling Pathways in BMS-833923-Treated hMSCs. To
understand the molecular mechanism by which BMS-
833923 reduces osteoblastic diﬀerentiation, we performed
global gene expression proﬁling in BMS-833923-treated
hMSCs compared to vehicle-treated controls. Heat-map clus-
tering revealed consistent changes in gene expression in BMS-
833923-treated hMSCs compared to controls (Figure 3(a)).
We identiﬁed 348 upregulated and 540 downregulated genes
(fold change ≥ 2:0; PðcorrÞ < 0:05) (Supplementary Tables 1
and 2). Pathway analysis of the downregulated genes
identiﬁed several diﬀerentially regulated signaling pathways
that are associated with osteoblastic diﬀerentiation including
GPCR, RANK-RANKL, insulin, TNF alpha and IL6, and
cytokine and inﬂammatory response signaling (Figure 3(b)).
A number of genes, including TNF, IL6, PLAU, CCL20,
VCAM1, CXCL1, CXCL2, and CXCL3, were selected for a
further validation using qRT-PCR, which together were in
concordance with the microarray data (Figure 3(c)).
To determine the possible mechanisms of action, we
determined the functional categories and signaling networks
regulated by BMS-833923 during osteoblastic diﬀerentiation
of hMSCs. The identiﬁed downregulated genes were sub-
jected to core signiﬁcance analysis using a manually curated
human functional annotation and network database
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Figure 1: Eﬀects of BMS-833923 treatment on the osteoblast diﬀerentiation of human bone marrow skeletal (mesenchymal) stem cells
(hMSCs). (a) Representative alkaline phosphatase (ALP) staining of BMS-833923-treated hMSCs (3.0 μM) on day 10 postosteoblastic
diﬀerentiation compared to DMSO-treated control cells. Magniﬁcation: 10x. (b) Quantiﬁcation of ALP activity in BMS-833923-treated
hMSCs (3.0 μM) on day 10 postosteoblastic diﬀerentiation compared to DMSO-treated control cells. (c) Assay for cell viability using
alamarBlue assay BMS-833923-treated hMSCs (3.0 μM) on day 10 postosteoblastic diﬀerentiation compared to DMSO-treated control
cells. Data are presented as mean ± SEM (n = 16). DMSO: dimethyl sulfoxide.
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Figure 2: Eﬀects of BMS-833923 treatment on human bone marrow skeletal (mesenchymal) stem cell (hMSC) functions in vitro. hMSCs
were induced to osteoblast diﬀerentiation in the presence of BMS-833923 (3.0μM) or vehicle (DMSO), and osteoblast diﬀerentiation was
determined by cytochemical staining with Alizarin red for an in vitro formed mineralized matrix (a) and expression of osteoblast-speciﬁc
genes by quantitative RT-PCR (b). Magniﬁcation: 10x. Data are presented as mean ± SEM, n = 6. ∗P < 0:05; ∗∗∗P < 0:0005. (c) Expression
of GLI1 and PCTH1 in hMSCs treated with BMS-833923 (3.0 μM) for 24 hours and measured using qRT-PCR, n = 6. Abbreviations:
ALP—alkaline phosphatase; COL1A1—collagen Type I Alpha 1; ON—osteonectin; DMSO—dimethyl sulfoxide; GLI1—GLI Family Zinc
Finger 1; PTCH1—patched 1.
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Figure 3: BMS-833923 exerts signiﬁcant eﬀects on multiple signaling pathways during osteoblast diﬀerentiation of human bone marrow
skeletal (mesenchymal) stem cells (hMSCs). hMSCs were induced to osteoblast diﬀerentiation in the presence of BMS-833923 (3.0 μM) or
vehicle (DMSO). (a) Heat map and unsupervised hierarchical clustering performed on diﬀerentially expressed genes during osteoblastic
diﬀerentiation. (b) Pie chart illustrating the distribution of selected intracellular signaling pathways enriched in the downregulated genes
identiﬁed in BMS-833923-treated hMSCs compared to DMSO-treated control cells. (c) Validation of a selected panel of downregulated
genes in BMS-833923-treated hMSCs compared to DMSO-treated control using qRT-PCR. Gene expression was normalized to β-actin.
Data are presented as mean fold change ± SEM (n = 6), ∗∗∗P < 0:0001.
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(Ingenuity Pathway Analysis). This analysis revealed a signif-
icant reduction in gene expression in several functional gene
categories including those involved in tissue development,
inﬂammatory responses, and connective tissue diseases
(Figure 4(a)). The tissue development functional category is
illustrated in Figure 4(b). Follow-up upstream regulator anal-
ysis characterized a number of suppressed networks includ-
ing TNF and NFκB and subsequent suppression of STAT
signaling (Figures 4(c) and 4(d)). The Connective Tissue
Disorder, Organismal Injury and Abnormality, and Skeletal
and Muscular Disorder networks were among the top identi-
ﬁed networks that are regulated in response to BMS-833923
treatment of hMSCs (Figure 4(e)). Our data suggest that
BMS-833923 plays a role in regulating the function of a num-
ber of signaling networks that are associated with the inhibi-
tion of osteoblastic diﬀerentiation of hMSCs.
3.3. BMS-833923 Reduced In Vivo Ectopic Bone Formation.
To further study the role of BMS-833923 in regulating osteo-
blast diﬀerentiation in vivo, we determined the amount of
bone formed in vivo by hMSCs treated with BMS-833923
or DMSO vehicle-treated control, following subcutaneous
implantation into immune deﬁcient mice. BMS-833923-
treated hMSCs exhibited a signiﬁcant reduction in ectopic
bone formation capacity (Figures 5(a)–5(b)). Quantitative
histological analysis revealed 90% (n = 3, P < 0:0001) reduc-
tion of bone area (Figure 5(c)) and 30% reduction in collagen
matrix formation (n = 3, P < 0:001) (Figure 5(d)).
4. Discussion
MSCs are multipotent stem cells that reside in the bone mar-
row and have the potential to diﬀerentiate into various
mesoderm-type cells including bone-forming osteoblasts
[5]. The molecular processes and intracellular signaling path-
ways regulating osteoblastic diﬀerentiation are under investi-
gation with the aim of better understanding the pathogenesis
of bone disorders and identifying novel approaches for
therapies [6, 20].
Chemical biology approaches employing small molecule
inhibitors targeting speciﬁc intracellular signaling pathways
have been widely employed to dissect molecular mechanisms
regulating stem cell fate due to their known mechanism of
action and biological potency that make them suitable for
use in both in vitro and in vivo studies [11, 12]. In the current
study, we identiﬁed BMS-833923, a small molecule inhibitor
of the Hh signaling pathway, through a small molecule
library screen, as a powerful inhibitor of osteoblast diﬀerenti-
ation of hMSCs in vitro and in vivo.
BMS-833923 is a small-molecule Smoothened (SMO)
inhibitor, and thus it inhibits the sonic hedgehog (SHH) sig-
naling. In the absence of Hh, a cell-surface transmembrane
protein Patched (PTCH) prevents the high expression and
activity of SMO. When extracellular Hh is present, it binds
to and inhibits Patched, allowing SMO to accumulate and
transmit intracellular signaling [2, 21, 22]. BMS-833923 has
been as an experimental oral drug in advanced cancer
patients due to its antiproliferative eﬀects. Here, we demon-
strate that BMS-833923 treatment can regulate stem cell
functions and that it can reduce osteoblast diﬀerentiation
both in vitro and in vivo.
Global gene expression proﬁling of hMSCs treated with
BMS-833923 identiﬁed signiﬁcant changes in several intra-
cellular signaling pathways including GPCR [23], pathways
involved in endochondral ossiﬁcation [24], RANK-RANKL
[25], insulin [26], TNF alpha [27], IL6 [28], and cytokine
and inﬂammatory response signaling [29] known to regulate
osteoblast diﬀerentiation and function. These data suggest
that hH signaling is not only important for embryonic bone
development but may also play a role in the regulation
of adult bone cells. During early stages of development,
Shh regulates the patterning of the future limb [30–32],
while Ihh acts later in the process of endochondral bone
formation in limb development. Together with parathyroid
hormone-related peptide, Ihh controls the growth plate
and long bone development [33–35]. Hh signaling also
plays a crucial role in dermal bone formation and intra-
membranous ossiﬁcation by regulating osteogenesis rather
than proliferation [36]. In adults, Hh signaling is required
for bone homeostasis [37]. Shh regulates osteoblast prolif-
eration and diﬀerentiation and osteoclast formation at the
remodeling site of fractures [38]. Notably, we did not
observe direct changes in HH genes based on the microar-
ray data; however, we observed the suppression of the
GPCR, which is downstream of the HH signaling pathway
(Figure 3(b)). This could be explained by the fact that the
microarray experiment was conducted on day 10 postdiﬀer-
entiation; therefore, at that time point, and since hMSCs have
already diﬀerentiated, we anticipate that the HH pathway is
no longer active in those cells. It is plausible that BMS-
833923 exerts its inhibitory eﬀects at an early stage during
hMSC diﬀerentiation (Figure 2(c), at 48 hrs). On day 10,
the most signiﬁcant changes were in processes related to oste-
ogenesis and cytokine production.
BMS-833923-treated hMSCs exhibited signiﬁcant
downregulation in members of the two major chemokine
subfamilies—CC and CXC, i.e., CXCL1, CXCL2, CXCL3,
CXCL8, CCL2, CCL20, CCL4L2, and CCL21 (Figure 3(c)
and Supplementary Table 2). These chemokines are known
to play a role during bone repair through the recruitment
of progenitor cells to bone regeneration sites [39, 40]. In
addition, we identiﬁed NFκB and STAT signaling among
the top inhibited signaling pathways in BMS-833923-
treated hMSCs; both are known to play a role in osteoblast
diﬀerentiation and bone formation.
BMS-833923 has been suggested to be relevant for the
therapy of a number of cancer types due to its eﬃcacy in inhi-
biting hH signaling. BMS-833923 inhibited the growth of
tumor cell lines derived from patients with hematological
malignancies such as CML, ALL, and AML [41] and it has
also in vivo inhibitory eﬀects on tumor growth of medullo-
blastoma and pancreatic carcinoma in animal models after
a single oral dose [21]. Finally, some studies have suggested
that BMS-833923 can be used in the management of cancer
bone diseases. In vitro treatment with BMS-833923 inhibited
the growth of myeloma cells and decreased the percentage of
ALDH+ cancer stem cells in the bone marrow of patients
with multiple myeloma [42, 43].
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Figure 4: Bioinformatic analysis of signaling networks regulated in BMS-833923-treated human bone marrow skeletal (mesenchymal) stem
cells (hMSCs). (a) Disease and function heat map depicting activation (red) or inhibition (blue) of the indicated functional and disease
categories identiﬁed in the downregulated transcripts in BMS-833923-treated hMSCs. (b) Heat map illustrating the tissue development
functional category. (c) Illustration of the TNF and (d) NFκB networks with predicted activated state based on transcriptome data. Figure
legend illustrates the interaction between molecules within the network. (e) Illustration of the connective tissue disorders, organismal
injury and abnormalities, and skeletal and muscular disorder network.
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To date, several clinical trials tested the safety and eﬃcacy
of BMS-833923 in various human cancers (https://
clinicaltrials.gov/); however, the eﬀect of BMS-833923 on
stem cell diﬀerentiation has not been addressed thus far. Cur-
rently, there are several FDA-approved sonic hedgehog
inhibitors for the treatment of patients with various cancers.
The majority of sonic hedgehog inhibitors target SMO
(i.e., Vismodegib and Sonidegib), while other inhibitors
target GLI1 (Arsenic Trioxide and Genistein) or SHH itself
(5E1 and Robotnikinin) [44]. BMS-833923 also targets
SMO; however, it remains to be addressed if variousHHpath-
way inhibitors exert similar eﬀects on hMSC diﬀerentiation.
5. Conclusions
Our results demonstrate the eﬃcient inhibition of osteoblast
function in vitro and in vivo suggesting that BMS-833923 can
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Figure 5: BMS-833923 reduces in vivo ectopic bone formation. BMS-833923-treated human bone marrow skeletal (mesenchymal) stem cells
(hMSCs) and vehicle-treated control cells were implanted with hydroxyl apatite/tricalcium phosphate (HA/TCP) subcutaneously into
immune deﬁcient mice. The histology of in vivo bone formation was examined in H&E- (a) and Sirius red- (b) stained sections. Black
arrows in (a) refer to formed bone. In Sirius red-stained slides (b), red color identiﬁes collagen tissue staining. Magniﬁcation: 10x (ﬁrst
row; scale bar = 200 μm) and 20x (second row; scale bar = 100 μm). n = 3 implants/treatment. ∗∗P < 0:001; ∗∗∗P < 0:0001. H&E:
hematoxylin and eosin.
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be employed in the treatment of bone diseases with enhanced
bone formation, e.g., sclerotic bone metastases.
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